S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CANF Can Fite BioPharma Ltd

1.8099

0.0199 (1.11%)

Jan 03 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma Ltd News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 30 December 2024 (5 days ago) • Edgar (US Regulatory)

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Monday 30 December 2024 (5 days ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 4 December 2024 (1 month ago) • Edgar (US Regulatory)

8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
Wednesday 4 December 2024 (1 month ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Monday 11 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 4 November 2024 (2 months ago) • Edgar (US Regulatory)

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Monday 4 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 18 October 2024 (3 months ago) • Edgar (US Regulatory)

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Friday 18 October 2024 (3 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 9 October 2024 (3 months ago) • Edgar (US Regulatory)

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Wednesday 9 October 2024 (3 months ago) • GlobeNewswire Inc.

More Can Fite BioPharma Ltd News Articles

Global Developments (PK)

Tonix Pharmaceuticals

Fannie Mae (QB)

Anavex Life Sciences

Bioelectronics (PK)

Code Green Apparel (PK)

GBT Technologies (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions